SAT672 Dulaglutide Might Reduce Visceral Fat In Patients With Metabolic Syndrome

Disclosure: Y. Kim: None. Liraglutide was shown to reduce visceral fat irrespective of T2DM status. However, due to cost and insurance coverage, dulaglutide has been prescribed more often than liraglutide in the clinical setting. This retrospective study aimed to evaluate the effect of dulaglutide on visceral fat among patients with metabolic syndrome. We reviewed medical records of patients aged ≥ 50 with metabolic syndrome and seen at a frailty clinic, where we measured body and visceral fat and BMI by bioelectrical impedance analysis and assessed frailty. One hundred ninety-six patients (average age 69.9, men 100, women 96) were seen from 12/1/2021 to 11/30/2022, and 53 patients were excluded due to missing data. Among 143 patients, five were taking dulaglutide when seen at the frailty clinic. We constructed a control group using matching sampling, but one patient was excluded because the matching pair was unavailable. We compared data between patients taking dulaglutide(study group) and the matched control group using a paired sample t-test. The % visceral fat of the dulaglutide group was lower than the control group (dulaglutide mean 10.75, control mean 11, P= 0.39). Three patients in the study group had the same % visceral fat as their paired control, and 2 out of 4 patients gained weight after starting dulaglutide. In this study, our study group was found to have lower % visceral fat on average than their paired control, although two patients gained weight. Given the small sample size, further studies with larger cohorts are needed to investigate this further. Presentation: Saturday, June 17, 2023